Abstract
Sorafenib increases overall survival in patients with advanced HCC by almost three months. However, despite these advances in the treatment of patients with HCC, average overall survival remains below one year. Based on our understanding of hepatocarcinogenesis, the development of new molecular targeting agents and results from biomarker studies in HCC, new therapeutic treatment options are currently being investigated. We summarize recent results on the molecular therapy for HCC and discuss how these can be efficiently tested in patients with HCC.
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Benzenesulfonates / adverse effects
-
Benzenesulfonates / therapeutic use*
-
Carcinoma, Hepatocellular / blood supply
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / pathology
-
Controlled Clinical Trials as Topic
-
Drug Delivery Systems
-
Humans
-
Liver Neoplasms / blood supply
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / pathology
-
Neoplasm Staging
-
Neovascularization, Pathologic / drug therapy
-
Neovascularization, Pathologic / pathology
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
Sorafenib
Substances
-
Antineoplastic Agents
-
Benzenesulfonates
-
Phenylurea Compounds
-
Pyridines
-
Niacinamide
-
Sorafenib